Christopher B. Ehrlich is Director at eFFECTOR Therapeutics, Inc. (EFTR). They have made 10 open-market trades across 4 companies since 2006, most recently 2024-09-25.
CIK 0001293973
10 open-market purchases totalling $13.1M since 2006, never a sale. Across 6 scored buys the stock is down 40.9% at ninety days, and 35.7 points behind the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 17% | 17% |
| Avg Move | -6.4% | -16.8% | -40.9% |
| Alpha | -5.0% | -16.3% | -35.7% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EFTR | BUY | 2022-10-04 | 2022-10-06 | $0.57 | $197 | -8.8% | -25.5% | +1.8% |
| EFTR | BUY | 2022-09-26 | 2022-09-27 | $0.55 | $10K | +7.5% | +4.3% | -28.8% |
| EFTR | BUY | 2022-02-14 | 2022-02-22 | $4.40 | $13K | -18.5% | -14.8% | -67.2% |
| EFTR | BUY | 2022-02-08 | 2022-02-10 | $4.84 | $10K | +8.7% | -17.6% | -51.9% |
| EFTR | BUY | 2022-02-03 | 2022-02-07 | $5.13 | $31K | -9.2% | -22.2% | -49.9% |
| EFTR | BUY | 2022-01-27 | 2022-01-31 | $5.30 | $27K | -18.1% | -24.6% | -49.4% |
| TSPT | BUY | 2011-09-20 | 2011-09-22 | $6.78 | $5.0M | N/A | N/A | N/A |
| BMTI | BUY | 2009-04-07 | 2009-04-08 | $8.50 | $8.0M | N/A | N/A | N/A |
| BMTI | BUY | 2006-05-15 | 2006-05-16 | $8.00 | $10K | N/A | N/A | N/A |
| CGTK | BUY | 2006-02-28 | 2006-03-01 | $9.02 | $20K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.